Fingolimod and changes in hematocrit, hemoglobin and red blood cells of patients with multiple sclerosis.

Ali Momeni, Rana Abrishamkar, Fatemeh Panahi, Sepehr Eslami, Nooshin Tavoosi, Aryan Rafiee Zadeh

RetractedAbstract readRetracted Publication

In one paragraph

Article in American journal of clinical and experimental immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Identifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human genetics.Nature genetics · 2022
Article

4 · The record

Corrections and comments

Retraction · 2019-10-15Ethical Violations by Author · Investigation by Journal/Publisher · Lack of IRB/IACUC Approval and/or Compliance ·
Retracted
Fingolimod and changes in hematocrit, hemoglobin and red blood cells of patients with multiple sclerosis [Retraction].2019

5 · Who and what money

Authors and funding

6 authors.

Ali MomeniSchool of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.

Rana AbrishamkarSchool of Medicine, Islamic Azad University, Najafabad Branch Isfahan, Iran.

Fatemeh PanahiSchool of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.

Sepehr EslamiDepartment of Orthopedics, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.

Nooshin TavoosiDepartment of Midwifery, School of Nursing and Midwifery, Islamic Azad University, Shahrekord Branch Shahrekord, Iran.

Aryan Rafiee ZadehSchool of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFingolimod is the first oral drug approved by Food and Drug Administration (FDA) of United States for treating patients with relapsing-remitting multiple sclerosis (RRMS). Fingolimod acts by immunomodulation but there are still much remained about its different effects.

objectivesThe aim of this study was to evaluate the changes in hematocrit (Hct), hemoglobin (Hb), and red blood cells (RBC) of patients with MS under treatments with fingolimod.

methodsA total number of 66 MS patients were included to our study based on certain exclusion criteria and eligibility for fingolimod oral treatment. Hct, Hb, and RBC were measured for each patient before drug administrations. Patients were treated with Fingolimod. 5 mg daily and after three months of treatments, measurements of Hct, Hb, and RBC were performed. Data were analyzed using SPSS software version 24.

resultsAmounts of Hct, Hb, and RBC were significantly decreased in this patient cohort. Hematocrit was decreased in all patients. Hemoglobin levels were significantly decreased in the female cohorts. Such decreases for male patients were insignificant. Red blood cell counts were also significantly decreased in patients.

conclusionAccumulating line of evidence had surveys on different side effects of fngolimod but here we indicated that fingolimod will also decrease amounts of Hct, Hb, and RBC which could result further problems in patients susceptible to other diseases.

Indexed as

hematocrithemoglobinMultiple sclerosisred blood cells

Identifiers

PMID31497380

PMCPMC6726974

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.